Key Points
- Director Robert Bessler sold 62,147 shares on April 24 at an average price of $7.05 for roughly $438,136, reducing his stake by 4.65% to 1,274,448 shares.
- LifeStance reported Q4 EPS of $0.03 versus a $0.05 estimate while revenue rose to $382.2M (+17.4% YoY); shares opened around $7.27 and were trading up about 3.1%, with a market cap near $2.82B.
- The board authorized a $100 million share buyback (about 3.6% of outstanding stock), and analysts maintain a consensus rating of "Moderate Buy" with an average price target of $9.83.
LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) Director Robert Bessler sold 62,147 shares of LifeStance Health Group stock in a transaction on Friday, April 24th. The shares were sold at an average price of $7.05, for a total value of $438,136.35. Following the transaction, the director owned 1,274,448 shares in the company, valued at $8,984,858.40. This represents a 4.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Robert Bessler also recently made the following trade(s):
- On Thursday, April 23rd, Robert Bessler sold 7,752 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.00, for a total value of $54,264.00.
- On Tuesday, April 21st, Robert Bessler sold 5,101 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.01, for a total value of $35,758.01.
LifeStance Health Group Trading Up 3.1%
Shares of NASDAQ LFST opened at $7.27 on Tuesday. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of 0.17. LifeStance Health Group, Inc. has a one year low of $3.74 and a one year high of $8.09. The business has a 50-day moving average price of $6.73 and a two-hundred day moving average price of $6.57. The firm has a market capitalization of $2.82 billion, a PE ratio of 363.68 and a beta of 1.13.
LifeStance Health Group (NASDAQ:LFST - Get Free Report) last issued its earnings results on Wednesday, February 25th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.05 by ($0.02). The business had revenue of $382.20 million during the quarter, compared to analyst estimates of $378.51 million. LifeStance Health Group had a net margin of 0.68% and a return on equity of 0.65%. LifeStance Health Group's revenue for the quarter was up 17.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.01) EPS. As a group, analysts predict that LifeStance Health Group, Inc. will post 0.09 earnings per share for the current fiscal year.
LifeStance Health Group declared that its board has authorized a stock buyback plan on Wednesday, February 25th that authorizes the company to repurchase $100.00 million in outstanding shares. This repurchase authorization authorizes the company to buy up to 3.6% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's board believes its shares are undervalued.
Institutional Trading of LifeStance Health Group
Large investors have recently added to or reduced their stakes in the business. Moran Wealth Management LLC bought a new stake in LifeStance Health Group in the first quarter worth $953,000. Inspire Investing LLC bought a new stake in shares of LifeStance Health Group during the 1st quarter worth about $1,602,000. Diversified Trust Co increased its holdings in shares of LifeStance Health Group by 14.8% during the 1st quarter. Diversified Trust Co now owns 21,532 shares of the company's stock valued at $137,000 after acquiring an additional 2,770 shares during the last quarter. Invesco Ltd. increased its holdings in shares of LifeStance Health Group by 6.9% during the 4th quarter. Invesco Ltd. now owns 205,486 shares of the company's stock valued at $1,447,000 after acquiring an additional 13,177 shares during the last quarter. Finally, Vident Advisory LLC raised its stake in shares of LifeStance Health Group by 148.8% in the 4th quarter. Vident Advisory LLC now owns 37,462 shares of the company's stock valued at $264,000 after acquiring an additional 22,406 shares in the last quarter. 85.50% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on LFST shares. Weiss Ratings raised shares of LifeStance Health Group from a "sell (d-)" rating to a "hold (c-)" rating in a research note on Friday, February 27th. KeyCorp upped their price target on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock an "overweight" rating in a research note on Thursday, February 26th. Barclays increased their price objective on LifeStance Health Group from $8.00 to $9.00 and gave the stock an "overweight" rating in a report on Friday, March 6th. UBS Group boosted their target price on LifeStance Health Group from $10.00 to $12.00 and gave the company a "buy" rating in a research note on Thursday, February 26th. Finally, Canaccord Genuity Group upped their target price on LifeStance Health Group from $9.00 to $10.00 and gave the stock a "buy" rating in a research report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, LifeStance Health Group presently has a consensus rating of "Moderate Buy" and an average price target of $9.83.
Read Our Latest Analysis on LifeStance Health Group
LifeStance Health Group Company Profile
(
Get Free Report)
LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.
The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
